Serum-soluble TRAIL levels in patients with severe persistent allergic asthma: Its relation to omalizumab treatment

Creative Commons License

Yalcin A. D., Bisgin A., Kargi A., Gorczynski R. M.

MEDICAL SCIENCE MONITOR, vol.18, no.3, 2012 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 18 Issue: 3
  • Publication Date: 2012
  • Doi Number: 10.12659/msm.882504
  • Journal Name: MEDICAL SCIENCE MONITOR
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Keywords: severe persistent allergic asthma, allergic asthma, soluble TRAIL, omalizumab, RHEUMATOID-ARTHRITIS, APOPTOSIS, RHINITIS, STRAIL, CELLS, EXPRESSION, SURVIVAL, LIGAND, DEATH, FAS
  • Çukurova University Affiliated: No

Abstract

Background: In this study we compare the Omalizumab treatment modality in the dynamics of cell apoptosis regulating molecules in both severe persistent asthma patients who had no other any allergic disease, newly diagnosed patients with allergic asthma, and healthy volunteers.